|Page (1) of 1 - 05/16/18||email article||print page|
Celldex Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting(May 16, 2018)
HAMPTON, N.J., May 16, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that two abstracts will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago.
The schedule for the presentations is as follows:
- Abstract TPS6091: “A phase 2, multicenter, open-label study to evaluate the efficacy and safety of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC)” (Bauman, et al)
Poster Session: Head and Neck Cancer
Location: Hall A
- Abstract 3001: “Anti-CD27 agonist antibody varlilumab with nivolumab for colorectal and ovarian cancer: Phase 1/2 clinical trial results” (Sanborn, et al)
Oral Abstract Session: Developmental Therapeutics—Immunotherapy
Date and Time: Saturday, June 2, 2018, 3:12 - 3:24 p.m. CDT
Location: Hall B1
Information in the abstracts, now available through ASCO’s website at https://am.asco.org, is current as of the time of submission.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes immunotherapies and other targeted biologics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Visit www.celldex.com.
Senior Vice President, Corporate Affairs & Administration
Associate Director, Investor Relations & Corp Communications